<DOC>
	<DOCNO>NCT01136057</DOCNO>
	<brief_summary>Treatment option limit treatment influenza . This study collect blood people expose influenza virus receive seasonal influenza vaccine . The blood plasma use future clinical trial treat people hospitalize influenza .</brief_summary>
	<brief_title>Blood Plasma Collection For Use Future Clinical Trials</brief_title>
	<detailed_description>There concern influenza virus become resistant standard care , oseltamivir ( commonly know Tamiflu ) , resistance medication observe people infected seasonal influenza virus . Because possibility drug resistance , additional treatment option influenza need . The purpose study collect blood people recover influenza received seasonal influenza vaccine . The blood process Food Drug Administration ( FDA ) -licensed fresh frozen plasma ( FFP ) . In future clinical trial , plasma use treatment people hospitalize influenza . This study enroll people recover influenza received seasonal influenza vaccine . Participants donate blood FDA-licensed blood donor center three time 240-day study period .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Currently healthy male 18 59 year age history suggestive antiinfluenza antibody ( either follow ) : 1 . An influenzalike illness ( e.g. , fever , chill , malaise , cough , myalgia , nausea ) . Subjects must asymptomatic must afebrile â‰¥ 7 day , must enroll within 12 month onset illness . 2 . Vaccinated licensed influenza vaccine . Enrollment must occur &gt; 14 day &lt; 12 month date vaccination . Must adult male Department Defense ( DoD ) /beneficiary Sign inform consent Health Insurance Portability Accountability Act ( HIPAA ) document A demonstrate H1N1 HAI titer 1:160 great H3N2 HAI titer 1:40 great . Must also meet StandardofCare inclusion criterion donation blood plasma FDAlicensed donor center prior every donation session . More information criterion find protocol . Donors meet StandardofCare FDA approve requirement donation blood production FFP determine FDAlicensed donor center prior every donation session may exclude participation study . Study exclusion determine principal investigator ( PI ) lead investigator study site . Donors fail StandardofCare screen Blood Borne Pathogen screen follow blood borne pathogen donor center exclude : 1 . AntiHIVI/II 2 . Antihuman Tlymphotropic virus ( HTLV ) I/II 3 . Antihepatitis C ( HCV ) 4 . Antihepatitis B core antigen ( HBc ) 5 . AntiT . cruzi ( enzyme immunoassay [ EIA ] Chagas disease ) ( require FDAlicensed donor center become nationwide FDA requirement ) 6 . Hepatitis B surface antigen ( HBsAg ) 7 . Serologic test syphilis 8 . HIV nucleic acid test ( NAT ) 9 . HCV NAT 10 . West Nile virus ( WNV ) NAT Participation medical research include : 1 . Studies currently ongoing start duration study require 60 mL blood donate 56day period time 2 . Administration unlicensed drug 3 month study entry duration study 3 . Administration unlicensed vaccine 12 month study entry duration study , exception unlicensed influenza vaccine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>